Familial Hypercholesterolemia in Children. The Current State of the Problem-Reference-Cited by-同舟云学术

Familial Hypercholesterolemia in Children. The Current State of the Problem

Published:2023-07-08 Issue:3 Volume:22 Page:231-240
ISSN:1682-5535
Container-title:Current Pediatrics
language:
Short-container-title:Vopr. sovr. pediatr.

Author:

Sadykova Dinara I.¹^ORCID,Salakhova Karina R.¹^ORCID,Galimova Liliya F.²^ORCID,Slastnikova Eugeniya S.²^ORCID,Khaliullina Chulpan D.³^ORCID

Affiliation:

1. Kazan State Medical University; Research Laboratory “Genetics and Clinic of Human Lipid Metabolism”, Kazan Federal University

2. Kazan State Medical University; Research Laboratory “Genetics and Clinic of Human Lipid Metabolism”, Kazan Federal University; Children’s Republican Clinical HospitalKazan

3. Kazan State Medical University

Abstract

Cardiovascular diseases are the leading cause of disability and mortality worldwide. Cardiovascular mortality rate is steadily increasing despite the large-scale preventive measures. Familial hypercholesterolemia is the most common genetically determined disorder of lipid metabolism as the major cause of blood circulatory system diseases development and progression. Worldwide, there are 6.8–8.5 million children with this primary dyslipidemia. Early (in childhood) diagnosis of familial hypercholesterolemia is crucial for the timely initiation of lipid-lowering therapy in order to reduce the atherosclerosis progression and the risk of life-threatening cardiovascular events. New screening programs have been implemented, new biomarkers of the disease have been studied, and lipid-lowering drugs with new mechanisms of hypolipidemic action have been developed to increase the efficacy of these activities in economically developed countries.

Publisher

Paediatrician Publishers LLC

Subject

Pediatrics, Perinatology and Child Health

Reference87 articles.

1. Cardiovascular diseases. In: World Health Organization: Official website. Available online: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1. Accessed on April 12, 2023.

2. Mal GS, Smakhtina AM. Secondary hyperlipidemia: definition, phenotypes and inducing factors. International Heart and Vascular Disease Journal. 2021;9(32):43-51. (In Russ). doi: https://doi.org/10.24412/2311-1623-2021-32-43-51

3. Thongtang N, Sukmawan R, Llanes EJB, Lee ZV. Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices. Preventive Medicine Reports. 2022;27:a101819. doi: https://doi.org/10.1016/j.pmedr.2022.101819

4. Kontsevaya AV, Balanova YA, Imaeva AE, et al. Economic burden of hypercholesterolemia in the Russian Federation. Rational pharmacotherapy in cardiology. 2018;14(3):393–401. doi: https://doi.org/10.20996/1819-6446-2018-14-3-393-401 (In Russ).

5. Sadykova DI, Lutfullin IY. Primary arterial hypertension and myocardial hypertrophy in children and adolescents. Pediatria. Journal n.a. G.N. Speransky. 2009;88(5): 16–21. (In Russ).